SBIR/STTR Research Award

Synthesis and Processing of Sulfonated Block Copolymer Biomaterials

Award identifier 44c192f28059efa31179da14489c0f29068c1fabe81f94d3fbbad2132d86cd7eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$98,521

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AEGIS BIOSCIENCES, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Aegis BioSciences has developed a new and versatile class of anionic, nanostructured hydrogel materials with promising applications in wound care, anti-thrombogenic coatings, and drug delivery. These multi-phase block copolymers are derived from inexpensive, commercially available materials which are subsequently sulfonated. Indeed, growing interest in these materials demands attention to larger-scale and efficient synthesis and processing which is the focus of this proposal. Potential technological innovations include (1) new and efficient methods of sulfonation to achieve biomaterials with broad functionality and low overall manufacturing cost, (2) new solvent combinations of for processing of these materials into films and coatings, and (3) the potential for the development of water-based dispersions for processing. We believe that each of these innovations are realizable given the resources of a Phase I effort. A real commercial application of materials resulting from these improved manufacturing processes is a drug-eluting stent coating, and potential applications include dressings for wound management and matrices for mucosal delivery of drugs. There is an urgent need for biomaterials with a broad range of functionality (e.g., drug delivery, low tendency to induce clotting, facilitation of wound healing) that have low raw materials costs. Aegis' biomaterials meet this need, and increased commercial interest is driving a desire to focus on manufacturing issues with attention to economical processes for material preparation and fabrication. This Phase I proposal addresses key needs for the expansion of Aegis' materials into a growing healthcare marketplace

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.